drugset / Trial / NCT06077331

A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

NCT06077331

Phase 2 Unknown 120 enrolled Hansoh BioMedical R&D Company
RandomizedParallel-groupDouble-blindTreatment

Summary

This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of moderate to severe plaque psoriasis. Additionally, this study is to find the optimal dosing for the future clinical development of HS-10374.

Timeline

Start
2023-09-28
Primary completion
2024-07-31
Completion
2024-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject HS-10374 Unknown 1 mg Oral
Subject HS-10374 Unknown 5 mg Oral

Indications